Clinical Trials on Antimetabolites, Antineoplastic

Total 45 results

Celgene

Completed

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) (apact)

Digestive System Diseases | Neoplasms | Neoplasms by Site | Endocrine System Diseases | Digestive System Neoplasms | Endocrine Gland Neoplasms | Pancreatic Neoplasms | Pancreatic Diseases | Gemcitabine | Antimetabolites, Antineoplastic

United States, Korea, Republic of, Canada, France, Spain, Belgium, Austria, Czechia, Denmark, Italy, Hong Kong, Singapore, Taiwan, Germany, Hungary, Australia, United Kingdom, Portugal, Ireland, Finland, Netherlands
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Huashan Hospital; The Second Affiliated Hospital of Harbin Medical University; Meng Chao Hepatobiliary Hospital of Fujian Medical University

Not yet recruiting

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Carcinoma | Digestive System Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Antineoplastic Agents | Oxaliplatin | Donafenib | Fluorouracil | Antimetabolites

China
University Hospital, Bonn

Completed

Tablet-based Patient Reported Outcome

Antineoplastic Agents

Germany
Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States
Bassett Healthcare

Active, not recruiting

Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?

Antineoplastic Agents

United States
University Hospital, Bordeaux
Bordeaux PharmacoEpi

Completed

Nurses Internal Contamination by Antineoplastic Drugs. (CACIES)

Antineoplastic Drugs Contamination Prevalence

France
University Hospital "Sestre Milosrdnice"

Completed

Responsible Side Effects Management in Oncology (R-SEMO)

Oncology | Pharmacovigilance | Antineoplastic Treatment

Croatia
R. Laura Vicente Vicente
Instituto de Investigación Biomédica de Salamanca; University of Salamanca; Hospital...

Recruiting

Immune Checkpoint Inhibitors Nephrotoxicity

Kidney Injury | Antineoplastics Toxicity

Spain
RenJi Hospital
BeiGene; Huidu Shanghai Medical Sciences Ltd

Recruiting

Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) (TACBIN-01)

Urologic Neoplasms | Urogenital Neoplasms | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Antineoplastic Agents | Tislelizumab Antineoplastic Agents, Immunological

China
Jilin University

Unknown

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Antineoplastic Combined Chemotherapy Protocols

China
Luzerner Kantonsspital
Inovise Medical

Completed

Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography

Antineoplastic Agents | Heart Failure, Congestive

Switzerland
Bio Sidus SA
IC RESEARCH GROUP

Completed

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia

Antineoplastic Chemotherapy Induced Anemia

Argentina
Celularity Incorporated
Lung Biotechnology PBC; California Institute for Regenerative Medicine (CIRM); ID...

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNKCOVID)

Coronaviridae Infections | Nidovirales Infections | RNA Virus Infections | Respiratory Tract Infections | Coronavirus Infection | Pneumonia, Viral | Pneumonia | Lung Diseases | ARDS | Coronavirus | Severe Acute Respiratory Syndrome Coronavirus 2 | Respiratory Tract Disease | Virus Disease | Physiological Effects of... and other conditions

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Jules Bordet Institute
Université Libre de Bruxelles; Fondation Kisane; Les Amis de l'Institut

Unknown

A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting (MADESIO)

Adults | Hematological Malignancy | Oral Antineoplastic Agents

Belgium
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
NEMA Research, Inc.

Completed

Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy

Peripheral Neuropathy | Antineoplastic Combined Chemotherapy Protocols

United States
Yonsei University
Inje University

Completed

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

Breast Neoplasms | Antineoplastic Agents | Therapeutic Uses | Survival Analysis

Korea, Republic of
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma (GALAXY-1)

Neoplasms | Antineoplastic Agents | Carcinoma, Squamous
Shanghai Bio-heart Biological Technology Co., Ltd.
CCRF Inc., Beijing, China

Active, not recruiting

Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

Coronary Artery Disease | Antineoplastic Agents

China
Centro di Riferimento Oncologico - Aviano

Recruiting

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA (MAGNETIC1)

Breast Neoplasms | Breast Diseases | Antineoplastic Agents | Aromatase Inhibitors | Neoplasms, Breast | Hormone Receptor Positive Breast Carcinoma | ESR1 Gene Mutation

Italy
Cairo University
National Cancer Institute, Egypt

Unknown

Prevention of Oral Mucositis After Using Chamomile Oral Cryotherapy Versus Oral Cryotherapy in Pediatric Cancer Patients Receiving Chemotherapy.

Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy

Egypt
Cairo University
National Cancer Institute (NCI)

Unknown

Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy

Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy

Egypt
Armando Orlandi

Completed

Erbitux MEtastatic Colorectal Cancer Strategy Study

Antineoplastic Agents

Italy
Novartis Pharmaceuticals

Completed

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Urogenital Neoplasms | Genital Neoplasms, Male | Prostatic Diseases | Antineoplastic Agents | Imatinib | Prostatic Neoplasm | Genital Diseases, Male | Neoplasms, Abdominal

Germany
Shandong University

Unknown

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia

Thrombocytopenia | Acute Myelocytic Leukemia | Antineoplastic Adverse Reaction

China
Tianjin Medical University Second Hospital

Not yet recruiting

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

Urogenital Neoplasms | Urothelial Carcinoma | Antineoplastic Agents | Gemcitabine | Cisplatin | Anlotinib | Carboplatin

China
Instituto Nacional de Cancerologia de Mexico

Unknown

Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.

Quality of Life | Breast Neoplasm | Antineoplastic Agents | Antiemetics

Mexico
Eli Lilly and Company

Active, not recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

Urogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditions

China, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

China
University Health Network, Toronto
University College London Hospitals; Brigham and Women's Hospital; University... and other collaborators

Recruiting

The STOP-MED CTRCD Trial (STOP-MED)

Heart Failure | Cancer | Cardiotoxicity | Cardiac Toxicity | Antineoplastics Toxicity

Canada, United States, United Kingdom, Australia
Wuhan Union Hospital, China

Not yet recruiting

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

Carcinoma | Intrahepatic Cholangiocarcinoma | Gallbladder Cancer | Immunotherapy | Tislelizumab | Surufatinib | Angiogenesis Inhibitors | Antineoplastic Agents, Immunological
Sichuan Cancer Hospital and Research Institute

Recruiting

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Liver Diseases | Digestive System Neoplasms | Liver Neoplasms | Hepatocellular Carcinoma | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action | Protein Kinase Inhibitors | Sorafenib

China
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab (TURANDORELA)

Neoplasms | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Urinary Bladder Diseases | Male Urogenital Diseases | Female Urogenital Diseases | Urinary Bladder Neoplasm | Female Urogenital Diseases and Pregnancy Complications | Antineoplastics Toxicity | Urogenital Diseases

Netherlands
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
National Cancer Institute, Slovakia
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Refractory Testicular Germ Cell Cancer.

Neoplasms | Gonadal Disorders | Neoplasms, Germ Cell and Embryonal | Testicular Neoplasms | Testicular Diseases | Antineoplastic Agents | Molecular Mechanisms of Pharmacological Action

Slovakia
Wenjun Cheng

Not yet recruiting

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Neoplasms by Histologic Type | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Angiogenesis | Genital Diseases, Female | Antineoplastic... and other conditions
Celularity Incorporated

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemorrhagic Disorders | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Antineoplastic Agents | Physiological... and other conditions

United States
Xiaoxiang Chen

Recruiting

Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ANLOLA)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Adnexal Diseases | Carcinoma, Ovarian Epithelial | Ovarian Cancer | Angiogenesis | Genital Diseases, Female | Antineoplastic Agents | BRCA1... and other conditions

China
MuReva Phototherapy Inc.

Recruiting

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients

Head and Neck Cancer | Oral Mucositis (Ulcerative) | Oral Mucositis (Ulcerative) Due to Radiation | Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy

United States
Xiaoxiang Chen

Unknown

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (AVANIRA3)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Adnexal Diseases | Gonadal Disorders | Endocrine Gland Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms and other conditions

China
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Fundación Instituto de Estudios de Ciencias de...
Instituto de Investigación Biomédica de Salamanca; Instituto de Salud Carlos...

Recruiting

Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial) (CARTIER)

Elderly | Cardiotoxicity | Antineoplastic Agents | Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)

Spain
Blueprint Medicines Corporation

Active, not recruiting

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditions

United States, Canada, Korea, Republic of, Japan, Taiwan
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States

Clinical Trials on Antimetabolites, Antineoplastic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations